Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Amoxicillin trihydrate; potassium clavulanate; Prednisolone
Norbrook Laboratories (Ireland) Limited
QJ51RV01
Amoxicillin trihydrate; potassium clavulanate; Prednisolone
200, 50, 10 mg/syringe
Intramammary suspension
POM: Prescription Only Medicine as defined in relevant national legislation
antibacterials and corticosteroids
Authorised
2018-11-30
Health Products Regulatory Authority 07 October 2020 CRN009Z9T Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Noroclav Intramammary Suspension for Lactating Cows 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each intramammary syringe of 3g contains: ACTIVE SUBSTANCES: Amoxicillin (as amoxicillin trihydrate) 200 mg Clavulanic acid (as potassium clavulanate) 50 mg Prednisolone 10 mg EXCIPIENTS: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Intramammary suspension Cream to buff oily suspension 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (lactating cows) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of clinical mastitis caused by the following bacteria susceptible to the combination of amoxicillin and clavulanic acid: Staphylococci (including β-lactamase producing strains) Streptococci (including _S. agalactiae, S. dysgalactiae_ and _S. uberis_) _Escherichia coli _(including β-lactamase producing strains) 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to the active substances, or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Do not use in cases associated with _Pseudomonas._ 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Swab teat end before treatment, with cleaning towels provided. RECOMMENDATIONS FOR PRUDENT USE The product should be used for treatment of clinical mastitis only. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the product is used. Health Products Regulatory Authority 07 October 2020 CRN009Z9T Page 2 of 5 The combination of amoxicillin and clavulanic acid should be reserved for the treatment of clinical conditions whic Read the complete document